CML诊疗重点分析.ppt

* ENESTnd: Comparison of Nilotinib and Imatinib in Newly Diagnosed CP CML Primary endpoint: MMR at 12 mos Secondary endpoint: durable MMR at 24 mos Other endpoints: time to MMR, CCyR by 12 mos, time to CCyR, EFS, PFS, OS, time to AP/BC on study treatment Patients diagnosed with Ph+ CP CML within 6 mos (N = 846) Nilotinib 300 mg BID (n = 282) Imatinib 400 mg QD (n = 283) Nilotinib 400 mg BID (n = 281) 5-yr follow-up Stratified by Sokal risk Saglio G, et al. N Engl J Med. 2010;362:2251-2259. * ENESTnd 3-Yr Update: Cumulative Molecular Responses 分子生物学反应 Larson RA, et al. Leukemia. 2012;[Epub ahe